scholarly journals STABLE CORONARY DISEASE IN HIGH VASCULAR RISK PATIENTS AND QUALITY OF LIFE: INSIGHTS FROM THE LONG TERM RISK, CLINICAL MANAGEMENT AND HEALTHCARE RESOURCE UTILIZATION OF STABLE CORONARY ARTERY DISEASE (TIGRIS) REGISTRY

2016 ◽  
Vol 67 (13) ◽  
pp. 2154
Author(s):  
David B. Brieger ◽  
Shaun Goodman ◽  
Jose Carlos Nicolau ◽  
Tabassome Simon ◽  
Jiyan Chen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Coronary Artery Disease ◽  
Healthcare Resource ◽  
Stable Coronary Artery Disease ◽  
Healthcare Resource Utilization ◽  
Vascular Risk ◽  
Risk Patients ◽  
Artery Disease

scholarly journals The argument of the ORBITA study: angioplasty is useless

2020 ◽  
Vol 22 (Supplement_E) ◽  
pp. E34-E36
Author(s):  
Leonardo Bolognese
Keyword(s):  
Quality Of Life ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Functional Capacity ◽  
Coronary Angioplasty ◽  
Stable Coronary Artery Disease ◽  
Artery Disease ◽  
Revascularization Procedures ◽  
Vessel Coronary Artery

Abstract The goal of treatment in stable coronary artery disease is to improve prognosis and quality of life of the patients. International Guidelines support revascularization procedures for symptomatic patients unresponsive to optimal medical treatment. Previous studies demonstrated, in fact, the therapeutic efficacy of coronary angioplasty in reducing angina and improving the functional capacity of these patients. The ORBITA study, recently published, challenged these assertions by demonstrating the lack of benefit of angioplasty over placebo in terms of effort tolerance in a population of patients with single-vessel coronary artery disease. What lesson could we learn from the ORBITA study?

Coronary artery disease: Prevention of cardiovascular disease

2010 ◽  
pp. 71-86
Author(s):  
Juan Carlos Kaski
Keyword(s):  
Quality Of Life ◽  
Cardiovascular Disease ◽  
Coronary Artery Disease ◽  
Cardiovascular Events ◽  
Improve Life Expectancy ◽  
Risk Patients ◽  
Coronary Artery Disease Prevention ◽  
Artery Disease ◽  
Prevention Of Cardiovascular Disease

Prevention of cardiovascular disease 72 Treatment 76 Cardioprotective agents 80 Trials supporting current recommendations 84 Further reading 86 The aim of prevention is to improve life expectancy and quality of life by reducing cardiovascular events in high-risk patients. Prevention is often described as primary, involving subjects who are at risk of developing cardiovascular disease (CVD) but are currently asymptomatic and have no evidence of CVD, or ...

Sign in / Sign up

Export Citation Format

Share Document